OncoMatch/Clinical Trials/NCT07157969
ICIs and Anti-VEGF Antibody/TKIs With or Without Interventional Therapy for Advanced HCC
Is NCT07157969 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments for hcc - hepatocellular carcinoma.
Treatment: Lenvatinib · Pembrolizumab · Atezolizumab · Bevacizumab · Camrelizumab · Apatinib · Tislelizumab · Sintilimab — This trial is designed to explore the efficacy and safety of interventional therapy combined with immune checkpoint inhibitors(ICIs) and anti-vascular endothelial growth factor(VEGF) antibody/tyrosine kinase inhibitors in the treatment of advanced hepatocellular carcinoma. Eligible participants will be divided into two groups based on their treatment plans: one receiving ICIs combined with anti-VEGF drugs, and the other receiving ICIs combined with anti-VEGF drugs alongside interventional therapy, which includes C-TACE, D-TACE, and HAIC. The specific number and interval of interventional therapy sessions will be determined according to the patient's individual condition. Researchers will closely monitor and rigorously evaluate the efficacy and safety of the treatment in participants through follow-up assessments. The primary endpoint is the objective response rate , while secondary endpoints include disease control rate, progression-free survival, overall survival, duration of response, adverse events, and serious adverse events.
Check if I qualifyExtracted eligibility criteria
Cancer type
Hepatocellular Carcinoma
Disease stage
Required: Stage BCLC STAGE B, BCLC STAGE C (BCLC)
BCLC Stage B or C
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: local-regional therapy
Received local-regional therapy within 4 weeks before the first dose of the study drug, including but not limited to surgery, radiotherapy, hepatic artery embolism, TACE, hepatic artery infusion, radiofrequency ablation, cryoablation, or percutaneous ethanol injection.
Lab requirements
Blood counts
adequate hematological function
Kidney function
adequate organ function
Liver function
Child-Pugh liver function class A or B
Child-Pugh liver function class A or B. Adequate hematological and organ function.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify